Acute decompensated heart failure: Update on new and emerging evidence and directions for future research

Michael M. Givertz, John R. Teerlink, Nancy M. Albert, Cheryl A. Westlake Canary, Sean P. Collins, Monica Colvin-Adams, Justin A. Ezekowitz, James C. Fang, Adrian F. Hernandez, Stuart D. Katz, Rajan Krishnamani, Wendy Gattis Stough, Mary N. Walsh, Javed Butler, Peter E. Carson, John P. Dimarco, Ray E. Hershberger, Joseph G. Rogers, John A. Spertus, William G. StevensonNancy K Sweitzer, W. H. Wilson Tang, Randall C. Starling

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Acute decompensated heart failure (ADHF) is a complex clinical event associated with excess morbidity and mortality. Managing ADHF patients is challenging because of the lack of effective treatments that both reduce symptoms and improve clinical outcomes. Existing guideline recommendations are largely based on expert opinion, but several recently published trials have yielded important data to inform both current clinical practice and future research directions. New insight has been gained regarding volume management, including dosing strategies for intravenous loop diuretics and the role of ultrafiltration in patients with heart failure and renal dysfunction. Although the largest ADHF trial to date (ASCEND-HF, using nesiritide) was neutral, promising results with other investigational agents have been reported. If these findings are confirmed in phase III trials, novel compounds, such as relaxin, omecamtiv mecarbil, and ularitide, among others, may become therapeutic options. Translation of research findings into quality clinical care can not be overemphasized. Although many gaps in knowledge exist, ongoing studies will address issues around delivery of evidence-based care to achieve the goal of improving the health status and clinical outcomes of patients with ADHF.

Original languageEnglish (US)
Pages (from-to)371-389
Number of pages19
JournalJournal of Cardiac Failure
Volume19
Issue number6
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Heart Failure
Relaxin
Sodium Potassium Chloride Symporter Inhibitors
Quality of Health Care
Brain Natriuretic Peptide
Ultrafiltration
Expert Testimony
Health Status
Direction compound
Guidelines
Morbidity
Kidney
Mortality
Therapeutics
Research

Keywords

  • biomarkers
  • clinical trials
  • diuretics
  • Heart failure
  • quality of care
  • ultrafiltration
  • vasodilators

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Givertz, M. M., Teerlink, J. R., Albert, N. M., Westlake Canary, C. A., Collins, S. P., Colvin-Adams, M., ... Starling, R. C. (2013). Acute decompensated heart failure: Update on new and emerging evidence and directions for future research. Journal of Cardiac Failure, 19(6), 371-389. https://doi.org/10.1016/j.cardfail.2013.04.002

Acute decompensated heart failure : Update on new and emerging evidence and directions for future research. / Givertz, Michael M.; Teerlink, John R.; Albert, Nancy M.; Westlake Canary, Cheryl A.; Collins, Sean P.; Colvin-Adams, Monica; Ezekowitz, Justin A.; Fang, James C.; Hernandez, Adrian F.; Katz, Stuart D.; Krishnamani, Rajan; Stough, Wendy Gattis; Walsh, Mary N.; Butler, Javed; Carson, Peter E.; Dimarco, John P.; Hershberger, Ray E.; Rogers, Joseph G.; Spertus, John A.; Stevenson, William G.; Sweitzer, Nancy K; Wilson Tang, W. H.; Starling, Randall C.

In: Journal of Cardiac Failure, Vol. 19, No. 6, 06.2013, p. 371-389.

Research output: Contribution to journalArticle

Givertz, MM, Teerlink, JR, Albert, NM, Westlake Canary, CA, Collins, SP, Colvin-Adams, M, Ezekowitz, JA, Fang, JC, Hernandez, AF, Katz, SD, Krishnamani, R, Stough, WG, Walsh, MN, Butler, J, Carson, PE, Dimarco, JP, Hershberger, RE, Rogers, JG, Spertus, JA, Stevenson, WG, Sweitzer, NK, Wilson Tang, WH & Starling, RC 2013, 'Acute decompensated heart failure: Update on new and emerging evidence and directions for future research', Journal of Cardiac Failure, vol. 19, no. 6, pp. 371-389. https://doi.org/10.1016/j.cardfail.2013.04.002
Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M et al. Acute decompensated heart failure: Update on new and emerging evidence and directions for future research. Journal of Cardiac Failure. 2013 Jun;19(6):371-389. https://doi.org/10.1016/j.cardfail.2013.04.002
Givertz, Michael M. ; Teerlink, John R. ; Albert, Nancy M. ; Westlake Canary, Cheryl A. ; Collins, Sean P. ; Colvin-Adams, Monica ; Ezekowitz, Justin A. ; Fang, James C. ; Hernandez, Adrian F. ; Katz, Stuart D. ; Krishnamani, Rajan ; Stough, Wendy Gattis ; Walsh, Mary N. ; Butler, Javed ; Carson, Peter E. ; Dimarco, John P. ; Hershberger, Ray E. ; Rogers, Joseph G. ; Spertus, John A. ; Stevenson, William G. ; Sweitzer, Nancy K ; Wilson Tang, W. H. ; Starling, Randall C. / Acute decompensated heart failure : Update on new and emerging evidence and directions for future research. In: Journal of Cardiac Failure. 2013 ; Vol. 19, No. 6. pp. 371-389.
@article{30a404e30e26429ebee9f90d72205d39,
title = "Acute decompensated heart failure: Update on new and emerging evidence and directions for future research",
abstract = "Acute decompensated heart failure (ADHF) is a complex clinical event associated with excess morbidity and mortality. Managing ADHF patients is challenging because of the lack of effective treatments that both reduce symptoms and improve clinical outcomes. Existing guideline recommendations are largely based on expert opinion, but several recently published trials have yielded important data to inform both current clinical practice and future research directions. New insight has been gained regarding volume management, including dosing strategies for intravenous loop diuretics and the role of ultrafiltration in patients with heart failure and renal dysfunction. Although the largest ADHF trial to date (ASCEND-HF, using nesiritide) was neutral, promising results with other investigational agents have been reported. If these findings are confirmed in phase III trials, novel compounds, such as relaxin, omecamtiv mecarbil, and ularitide, among others, may become therapeutic options. Translation of research findings into quality clinical care can not be overemphasized. Although many gaps in knowledge exist, ongoing studies will address issues around delivery of evidence-based care to achieve the goal of improving the health status and clinical outcomes of patients with ADHF.",
keywords = "biomarkers, clinical trials, diuretics, Heart failure, quality of care, ultrafiltration, vasodilators",
author = "Givertz, {Michael M.} and Teerlink, {John R.} and Albert, {Nancy M.} and {Westlake Canary}, {Cheryl A.} and Collins, {Sean P.} and Monica Colvin-Adams and Ezekowitz, {Justin A.} and Fang, {James C.} and Hernandez, {Adrian F.} and Katz, {Stuart D.} and Rajan Krishnamani and Stough, {Wendy Gattis} and Walsh, {Mary N.} and Javed Butler and Carson, {Peter E.} and Dimarco, {John P.} and Hershberger, {Ray E.} and Rogers, {Joseph G.} and Spertus, {John A.} and Stevenson, {William G.} and Sweitzer, {Nancy K} and {Wilson Tang}, {W. H.} and Starling, {Randall C.}",
year = "2013",
month = "6",
doi = "10.1016/j.cardfail.2013.04.002",
language = "English (US)",
volume = "19",
pages = "371--389",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Acute decompensated heart failure

T2 - Update on new and emerging evidence and directions for future research

AU - Givertz, Michael M.

AU - Teerlink, John R.

AU - Albert, Nancy M.

AU - Westlake Canary, Cheryl A.

AU - Collins, Sean P.

AU - Colvin-Adams, Monica

AU - Ezekowitz, Justin A.

AU - Fang, James C.

AU - Hernandez, Adrian F.

AU - Katz, Stuart D.

AU - Krishnamani, Rajan

AU - Stough, Wendy Gattis

AU - Walsh, Mary N.

AU - Butler, Javed

AU - Carson, Peter E.

AU - Dimarco, John P.

AU - Hershberger, Ray E.

AU - Rogers, Joseph G.

AU - Spertus, John A.

AU - Stevenson, William G.

AU - Sweitzer, Nancy K

AU - Wilson Tang, W. H.

AU - Starling, Randall C.

PY - 2013/6

Y1 - 2013/6

N2 - Acute decompensated heart failure (ADHF) is a complex clinical event associated with excess morbidity and mortality. Managing ADHF patients is challenging because of the lack of effective treatments that both reduce symptoms and improve clinical outcomes. Existing guideline recommendations are largely based on expert opinion, but several recently published trials have yielded important data to inform both current clinical practice and future research directions. New insight has been gained regarding volume management, including dosing strategies for intravenous loop diuretics and the role of ultrafiltration in patients with heart failure and renal dysfunction. Although the largest ADHF trial to date (ASCEND-HF, using nesiritide) was neutral, promising results with other investigational agents have been reported. If these findings are confirmed in phase III trials, novel compounds, such as relaxin, omecamtiv mecarbil, and ularitide, among others, may become therapeutic options. Translation of research findings into quality clinical care can not be overemphasized. Although many gaps in knowledge exist, ongoing studies will address issues around delivery of evidence-based care to achieve the goal of improving the health status and clinical outcomes of patients with ADHF.

AB - Acute decompensated heart failure (ADHF) is a complex clinical event associated with excess morbidity and mortality. Managing ADHF patients is challenging because of the lack of effective treatments that both reduce symptoms and improve clinical outcomes. Existing guideline recommendations are largely based on expert opinion, but several recently published trials have yielded important data to inform both current clinical practice and future research directions. New insight has been gained regarding volume management, including dosing strategies for intravenous loop diuretics and the role of ultrafiltration in patients with heart failure and renal dysfunction. Although the largest ADHF trial to date (ASCEND-HF, using nesiritide) was neutral, promising results with other investigational agents have been reported. If these findings are confirmed in phase III trials, novel compounds, such as relaxin, omecamtiv mecarbil, and ularitide, among others, may become therapeutic options. Translation of research findings into quality clinical care can not be overemphasized. Although many gaps in knowledge exist, ongoing studies will address issues around delivery of evidence-based care to achieve the goal of improving the health status and clinical outcomes of patients with ADHF.

KW - biomarkers

KW - clinical trials

KW - diuretics

KW - Heart failure

KW - quality of care

KW - ultrafiltration

KW - vasodilators

UR - http://www.scopus.com/inward/record.url?scp=84878588169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878588169&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2013.04.002

DO - 10.1016/j.cardfail.2013.04.002

M3 - Article

C2 - 23743486

AN - SCOPUS:84878588169

VL - 19

SP - 371

EP - 389

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 6

ER -